Details of the Drug

General Information of Drug (ID: DMCDYW7)

Drug Name
Nicardipine
Synonyms
Nicardipino; Nicardipinum; Cardene IV; Nicardipine LA; Cardene (TN); Nicardipine (INN); Nicardipine [INN:BAN]; Nicardipino [INN-Spanish]; Nicardipinum [INN-Latin]; Y-93; Methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-(Benzylmethylamino)ethylmethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester; 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Indication
Disease Entry ICD 11 Status REF
High blood pressure BA00 Approved [1], [2]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 479.5
Topological Polar Surface Area (xlogp) 3.8
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The clearance of drug is 0.4 L/h/kg [4]
Elimination
0% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 8.6 hours [5]
Metabolism
The drug is metabolized via the liver [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.17068 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.01% [5]
Vd
The volume of distribution (Vd) of drug is 8.3 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 7.9 mg/mL [3]
Chemical Identifiers
Formula
C26H29N3O6
IUPAC Name
5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES
CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC
InChI
InChI=1S/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3
InChIKey
ZBBHBTPTTSWHBA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4474
ChEBI ID
CHEBI:7550
CAS Number
55985-32-5
DrugBank ID
DB00622
TTD ID
D0T0KA
VARIDT ID
DR00280
INTEDE ID
DR1144
ACDINA ID
D00465

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium channel unspecific (CaC) TT5HONZ NOUNIPROTAC Blocker [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [12]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nicardipine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Nadolol DMW6GVL Moderate Increased risk of cardiac depression by the combination of Nicardipine and Nadolol. Essential hypertension [BA00] [70]
Coadministration of a Drug Treating the Disease Different from Nicardipine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Major Increased metabolism of Nicardipine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [71]
Magnesium Sulfate DMVEK07 Moderate Additive hypotensive effects by the combination of Nicardipine and Magnesium Sulfate. Acute pain [MG31] [72]
Emapalumab DMZG5WL Moderate Altered metabolism of Nicardipine due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [73]
Mitotane DMU1GX0 Major Increased metabolism of Nicardipine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [71]
Siltuximab DMGEATB Moderate Altered metabolism of Nicardipine due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [73]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Nicardipine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [74]
Posaconazole DMUL5EW Moderate Decreased metabolism of Nicardipine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [75]
Zileuton DMVRIC2 Minor Decreased metabolism of Nicardipine caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [76]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Nicardipine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [77]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Nicardipine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [78]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Nicardipine and Cariprazine. Bipolar disorder [6A60] [79]
Erdafitinib DMI782S Moderate Increased metabolism of Nicardipine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [80]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Nicardipine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [81]
Tucatinib DMBESUA Moderate Decreased metabolism of Nicardipine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [82]
Mifepristone DMGZQEF Moderate Decreased metabolism of Nicardipine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [83]
Pasireotide DMHM7JS Moderate Increased risk of atrioventricular block by the combination of Nicardipine and Pasireotide. Cushing syndrome [5A70] [84]
Lumacaftor DMCLWDJ Major Increased metabolism of Nicardipine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [71]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Nicardipine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [85]
MK-8228 DMOB58Q Moderate Decreased metabolism of Nicardipine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [86]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Nicardipine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [87]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Nicardipine and Selegiline. Depression [6A70-6A7Z] [88]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Nicardipine and Isocarboxazid. Depression [6A70-6A7Z] [88]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Nicardipine and Tranylcypromine. Depression [6A70-6A7Z] [88]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Nicardipine and OPC-34712. Depression [6A70-6A7Z] [79]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Nicardipine and Phenelzine. Depression [6A70-6A7Z] [88]
Primidone DM0WX6I Major Increased metabolism of Nicardipine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Cenobamate DMGOVHA Moderate Increased metabolism of Nicardipine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [89]
Stiripentol DMMSDOY Moderate Decreased metabolism of Nicardipine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [90]
Fosphenytoin DMOX3LB Major Increased metabolism of Nicardipine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Ethotoin DMXWOCP Moderate Increased metabolism of Nicardipine caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [91]
Phenobarbital DMXZOCG Major Increased metabolism of Nicardipine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [71]
Tazemetostat DMWP1BH Moderate Increased metabolism of Nicardipine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [92]
Miconazole DMPMYE8 Moderate Decreased metabolism of Nicardipine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [75]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Nicardipine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [75]
Metipranolol DMJMVKI Moderate Increased risk of cardiac depression by the combination of Nicardipine and Metipranolol. Glaucoma [9C61] [93]
Levobetaxolol DMSREPX Moderate Increased risk of cardiac depression by the combination of Nicardipine and Levobetaxolol. Glaucoma [9C61] [93]
Levobunolol DMTNFCQ Moderate Increased risk of cardiac depression by the combination of Nicardipine and Levobunolol. Glaucoma [9C61] [93]
Carvedilol DMHTEAO Moderate Increased risk of cardiac depression by the combination of Nicardipine and Carvedilol. Heart failure [BD10-BD1Z] [70]
Boceprevir DMBSHMF Moderate Decreased metabolism of Nicardipine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [94]
Simeprevir DMLUA9D Moderate Decreased metabolism of Nicardipine caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [95]
Telaprevir DMMRV29 Moderate Decreased metabolism of Nicardipine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [94]
Rifampin DMA8J1G Major Increased metabolism of Nicardipine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [71]
Rifapentine DMCHV4I Major Increased metabolism of Nicardipine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [71]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Nicardipine and Procarbazine. Hodgkin lymphoma [2B30] [88]
Delavirdine DM3NF5G Moderate Decreased metabolism of Nicardipine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [96]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Nicardipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [97]
Cobicistat DM6L4H2 Moderate Decreased clearance of Nicardipine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [98]
Tipranavir DM8HJX6 Moderate Accelerated clearance of Nicardipine due to the transporter induction by Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [99]
Efavirenz DMC0GSJ Moderate Increased metabolism of Nicardipine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [100]
Saquinavir DMG814N Moderate Decreased metabolism of Nicardipine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [101]
Etravirine DMGV8QU Moderate Increased metabolism of Nicardipine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [102]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Nicardipine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [97]
Darunavir DMN3GCH Moderate Decreased metabolism of Nicardipine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [103]
Atazanavir DMSYRBX Moderate Decreased metabolism of Nicardipine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [104]
Acebutolol DM0TI4U Moderate Increased risk of cardiac depression by the combination of Nicardipine and Acebutolol. Hypertension [BA00-BA04] [70]
Penbutolol DM4ES8F Moderate Increased risk of cardiac depression by the combination of Nicardipine and Penbutolol. Hypertension [BA00-BA04] [70]
Nebivolol DM7F1PA Moderate Increased risk of cardiac depression by the combination of Nicardipine and Nebivolol. Hypertension [BA00-BA04] [70]
Pindolol DMD2NV7 Moderate Increased risk of cardiac depression by the combination of Nicardipine and Pindolol. Hypertension [BA00-BA04] [70]
Conivaptan DM1V329 Moderate Decreased metabolism of Nicardipine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [105]
Lesinurad DMUR64T Moderate Increased metabolism of Nicardipine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [106]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Nicardipine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [107]
Amobarbital DM0GQ8N Moderate Increased metabolism of Nicardipine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [74]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Nicardipine and Propiomazine. Insomnia [7A00-7A0Z] [79]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Nicardipine and ITI-007. Insomnia [7A00-7A0Z] [79]
PF-06463922 DMKM7EW Moderate Increased metabolism of Nicardipine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [108]
Selpercatinib DMZR15V Moderate Decreased metabolism of Nicardipine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [73]
Idelalisib DM602WT Moderate Decreased metabolism of Nicardipine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [109]
GDC-0199 DMH0QKA Moderate Decreased metabolism of Nicardipine caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [83]
IPI-145 DMWA24P Moderate Decreased metabolism of Nicardipine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [110]
LGX818 DMNQXV8 Moderate Increased metabolism of Nicardipine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [111]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Nicardipine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [73]
Exjade DMHPRWG Moderate Decreased metabolism of Nicardipine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [112]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Nicardipine and Thalidomide. Multiple myeloma [2A83] [83]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Nicardipine and Siponimod. Multiple sclerosis [8A40] [83]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Nicardipine and Fingolimod. Multiple sclerosis [8A40] [113]
Ozanimod DMT6AM2 Moderate Increased risk of bradycardia by the combination of Nicardipine and Ozanimod. Multiple sclerosis [8A40] [114]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Nicardipine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [73]
Dasatinib DMJV2EK Moderate Decreased metabolism of Nicardipine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [115]
Modafinil DMYILBE Moderate Increased metabolism of Nicardipine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [83]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Nicardipine and Promethazine. Nausea/vomiting [MD90] [79]
Entrectinib DMMPTLH Moderate Decreased metabolism of Nicardipine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [116]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Nicardipine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [117]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Nicardipine and Safinamide. Parkinsonism [8A00] [88]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Nicardipine and Rasagiline. Parkinsonism [8A00] [88]
Abametapir DM2RX0I Moderate Decreased metabolism of Nicardipine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [118]
Lefamulin DME6G97 Moderate Decreased metabolism of Nicardipine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [119]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Nicardipine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [120]
Enzalutamide DMGL19D Major Increased metabolism of Nicardipine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [71]
Silodosin DMJSBT6 Moderate Decreased clearance of Nicardipine due to the transporter inhibition by Silodosin. Prostate hyperplasia [GA90] [121]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Nicardipine due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [73]
Ixekizumab DMXW92T Moderate Altered metabolism of Nicardipine due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [73]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Nicardipine and Levomepromazine. Psychotic disorder [6A20-6A25] [79]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Nicardipine and Fluphenazine. Psychotic disorder [6A20-6A25] [79]
Everolimus DM8X2EH Moderate Decreased metabolism of Nicardipine caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [122]
Tocilizumab DM7J6OR Moderate Altered metabolism of Nicardipine due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [73]
Canakinumab DM8HLO5 Moderate Altered metabolism of Nicardipine due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [73]
Rilonacept DMGLUQS Moderate Altered metabolism of Nicardipine due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [73]
Golimumab DMHZV7X Moderate Altered metabolism of Nicardipine due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [73]
Sarilumab DMOGNXY Moderate Altered metabolism of Nicardipine due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [73]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Nicardipine and Quetiapine. Schizophrenia [6A20] [79]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Nicardipine and Mesoridazine. Schizophrenia [6A20] [79]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Nicardipine and Thioridazine. Schizophrenia [6A20] [79]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Nicardipine and Aripiprazole. Schizophrenia [6A20] [79]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Nicardipine and Iloperidone. Schizophrenia [6A20] [79]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Nicardipine and Paliperidone. Schizophrenia [6A20] [79]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Nicardipine and Perphenazine. Schizophrenia [6A20] [79]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Nicardipine and Molindone. Schizophrenia [6A20] [79]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Nicardipine and Thiothixene. Schizophrenia [6A20] [79]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Nicardipine and Trifluoperazine. Schizophrenia [6A20] [79]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Nicardipine and Risperidone. Schizophrenia [6A20] [79]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Nicardipine and Amisulpride. Schizophrenia [6A20] [79]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Nicardipine and Asenapine. Schizophrenia [6A20] [79]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Nicardipine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [123]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Nicardipine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [73]
Larotrectinib DM26CQR Moderate Decreased metabolism of Nicardipine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [83]
Armodafinil DMGB035 Moderate Increased metabolism of Nicardipine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [83]
LEE011 DMMX75K Moderate Decreased metabolism of Nicardipine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [124]
Pitolisant DM8RFNJ Moderate Increased metabolism of Nicardipine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [73]
Fostamatinib DM6AUHV Moderate Decreased clearance of Nicardipine due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [125]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Nicardipine due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [117]
Tacrolimus DMZ7XNQ Moderate Decreased metabolism of Nicardipine caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [126]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Nicardipine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [79]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Nicardipine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [127]
⏷ Show the Full List of 123 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nicardipine 30 mg capsule 30 mg Oral Capsule Oral
Nicardipine 20 mg capsule 20 mg Oral Capsule Oral
Nicardipine 30 mg capsule 30 mg 12 HR Extended Release Capsule Oral
Nicardipine 45 mg capsule 45 mg 12 HR Extended Release Capsule Oral
Nicardipine 60 mg capsule 60 mg 12 HR Extended Release Capsule Oral
Nicardipine 30 mg capsule 30 mg 12 HR Extended Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2559).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022276.
3 BDDCS applied to over 900 drugs
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
9 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10 Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
11 Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
12 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
23 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
24 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
25 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
26 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
27 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
28 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
29 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
30 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
31 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
32 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
33 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
34 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
35 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
36 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
37 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
38 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
39 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
40 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
41 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
42 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
43 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
44 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
45 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
46 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
47 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
48 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
49 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
50 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
51 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
52 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
53 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
54 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
55 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
56 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
57 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
58 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
59 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
60 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
61 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
62 RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
63 Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
64 Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
65 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
66 Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
67 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
68 Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
69 Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
70 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
71 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
72 Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
73 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
74 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
75 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
76 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
77 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
78 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
79 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
80 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
81 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
82 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
83 Cerner Multum, Inc. "Australian Product Information.".
84 Canadian Pharmacists Association.
85 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
86 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
87 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
88 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
89 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
90 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
91 Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
92 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
93 Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
94 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
95 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
96 Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
97 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
98 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
99 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
100 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
101 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
102 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
103 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
104 Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
105 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
106 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
107 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
108 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
109 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
110 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
111 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
112 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
113 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
114 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
115 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
116 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
117 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
118 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
119 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
120 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
121 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
122 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
123 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
124 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
125 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
126 Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161]
127 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.